Nasdaq · CIK 0001053691
CRVO CervoMed Inc.
Insider trading from SEC Form 4. Last filing Jun 15, 2026. Close $3.22 on Oct 9, 2026, +43% from the 52-week low and -68% from the high.
In brief
CervoMed Inc. (CRVO) has 51 SEC Form 4 filings on file from 13 insiders, the latest filed on Jun 15, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
12 open-market trades have been scored at CRVO. The newest: Joshua S Boger (director and 10% owner) bought $3.0M of stock on Jun 11, 2026, filed Jun 15, 2026, scored 68 (notable). 4 insiders bought within 14 days of each other around Nov 17, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at CervoMed Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 68Notable | Joshua S Boger director, owner buy | $3.0M 955,414 shares | +114% | +8% from low-77% from high | |
| 57Moderate | John J Alam CEO & President buy | $183k 21,600 shares | +1% | - | |
| 53Moderate | William Robert Elder CFO, GC & Secretary buy | $29k 3,500 shares | +39% | - | |
| 47Moderate | Sylvie Gregoire director, owner buy | $183k 21,600 shares | +1% | - | |
| 51Moderate | Matthew Winton Chief Commercial and Business buy | $41k 5,000 shares | +50% | - | |
| 47Moderate | John J Alam CEO & President buy | $59k 7,847 shares | +1% | - | |
| 46Moderate | Matthew Winton Chief Commercial and Business buy | $76k 10,000 shares | - | - | |
| 37Weak | Sylvie Gregoire director, owner buy | $59k 7,847 shares | +1% | - | |
| 41Moderate | John J Alam CEO & President buy | $41k 5,553 shares | +0% | - | |
| 52Moderate | William Robert Elder CFO, GC & Secretary buy | $26k 3,500 shares | +64% | - | |
| 31Weak | Sylvie Gregoire director, owner buy | $41k 5,553 shares | +0% | - | |
| 38Weak | William Robert Elder CFO, GC & Secretary buy | $36k 4,233 shares | +334% | - |
Transactions
The newest 50 of 63 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Joshua S Boger director, owner | POpen-market purchase Common Stockindirect: By Trusts | +955,414 | $3.14 | $3.0M | 1,795,865 | Jun 15, 2026 |
| Jun 11, 2026 | Joshua S Boger director, owner | POpen-market purchase Series B Warrantsderivativeindirect: By Trust | +955,414 | - | - | 955,414 | Jun 15, 2026 |
| Jun 11, 2026 | Joshua S Boger director, owner | POpen-market purchase Series C Warrantsderivativeindirect: By Trust | +955,414 | - | - | 955,414 | Jun 15, 2026 |
| Jun 8, 2026 | John J Alam CEO & President | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Spouse | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Jun 8, 2026 | Jane H Hollingsworth director | AGrant or award Stock Option (Right to Buy)derivative | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Jun 8, 2026 | Marwan Sabbagh director | AGrant or award Stock Option (Right to Buy)derivative | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Jun 8, 2026 | Frank Zavrl director | AGrant or award Stock Option (Right to Buy)derivative | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Jun 8, 2026 | Joshua S Boger director, owner | AGrant or award Stock Option (Right to Buy)derivative | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Jun 8, 2026 | David Quigley director | AGrant or award Stock Option (Right to Buy)derivative | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Jun 8, 2026 | Jeffrey V. Poulton director | AGrant or award Stock Option (Right to Buy)derivative | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Jun 8, 2026 | Sylvie Gregoire director, owner | AGrant or award Stock Option (Right to Buy)derivative | +8,150 | $0.00 | $0 | 8,150 | Jun 10, 2026 |
| Feb 11, 2026 | Sylvie Gregoire director, owner | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Spouse | +75,000 | $0.00 | $0 | 75,000 | Feb 13, 2026 |
| Feb 11, 2026 | Matthew Winton Chief Commercial and Business | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 13, 2026 |
| Feb 11, 2026 | John J Alam CEO & President | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Feb 13, 2026 |
| Feb 11, 2026 | Kelly Blackburn EVP, Clinical Development | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 13, 2026 |
| Feb 11, 2026 | Mark De Rosch EVP, RA and GA and PgM | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 13, 2026 |
| Feb 11, 2026 | William Robert Elder CFO, GC & Secretary | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 13, 2026 |
| Oct 27, 2025 | David Quigley director | AGrant or award Stock Option (Right to Buy)derivative | +16,200 | $0.00 | $0 | 16,200 | Dec 5, 2025 |
| Nov 17, 2025 | John J Alam CEO & President | POpen-market purchase Common Stock | +10,807 | $8.46 | $91k | 1,484,078 | Nov 19, 2025 |
| Nov 17, 2025 | William Robert Elder CFO, GC & Secretary | POpen-market purchase Common Stock | +1,000 | $8.45 | $8,450 | 10,000 | Nov 19, 2025 |
| Nov 17, 2025 | Sylvie Gregoire director, owner | POpen-market purchase Common Stock | +10,793 | $8.46 | $91k | 1,484,078 | Nov 19, 2025 |
| Nov 17, 2025 | Matthew Winton Chief Commercial and Business | POpen-market purchase Common Stock | +3,500 | $8.43 | $30k | 13,500 | Nov 19, 2025 |
| Nov 18, 2025 | William Robert Elder CFO, GC & Secretary | POpen-market purchase Common Stock | +2,500 | $8.32 | $21k | 12,500 | Nov 19, 2025 |
| Nov 18, 2025 | Matthew Winton Chief Commercial and Business | POpen-market purchase Common Stock | +1,500 | $7.95 | $12k | 15,000 | Nov 19, 2025 |
| Nov 17, 2025 | John J Alam CEO & President | POpen-market purchase Common Stockindirect: Spouse's IRA | +10,793 | $8.46 | $91k | 12,500 | Nov 19, 2025 |
| Nov 17, 2025 | Sylvie Gregoire director, owner | POpen-market purchase Common Stockindirect: Spouse's IRA | +10,807 | $8.46 | $91k | 12,500 | Nov 19, 2025 |
| Nov 13, 2025 | Sylvie Gregoire director, owner | POpen-market purchase Common Stock | +4,447 | $7.51 | $33k | 1,471,578 | Nov 17, 2025 |
| Nov 14, 2025 | Matthew Winton Chief Commercial and Business | POpen-market purchase Common Stock | +10,000 | $7.57 | $76k | 10,000 | Nov 17, 2025 |
| Nov 13, 2025 | John J Alam CEO & President | POpen-market purchase Common Stock | +4,447 | $7.51 | $33k | 1,471,578 | Nov 17, 2025 |
| Nov 14, 2025 | John J Alam CEO & President | POpen-market purchase Common Stock | +1,693 | $7.55 | $13k | 1,473,271 | Nov 17, 2025 |
| Nov 14, 2025 | Sylvie Gregoire director, owner | POpen-market purchase Common Stock | +1,707 | $7.57 | $13k | 1,473,285 | Nov 17, 2025 |
| Nov 14, 2025 | John J Alam CEO & President | POpen-market purchase Common Stockindirect: Spouse's IRA | +1,707 | $7.57 | $13k | 1,707 | Nov 17, 2025 |
| Nov 14, 2025 | Sylvie Gregoire director, owner | POpen-market purchase Common Stockindirect: Spouse's IRA | +1,693 | $7.55 | $13k | 1,693 | Nov 17, 2025 |
| Nov 12, 2025 | John J Alam CEO & President | POpen-market purchase Common Stock | +5,553 | $7.35 | $41k | 1,467,131 | Nov 13, 2025 |
| Nov 12, 2025 | William Robert Elder CFO, GC & Secretary | POpen-market purchase Common Stock | +3,500 | $7.44 | $26k | 9,000 | Nov 13, 2025 |
| Nov 12, 2025 | Sylvie Gregoire director, owner | POpen-market purchase Common Stock | +5,553 | $7.35 | $41k | 1,467,131 | Nov 13, 2025 |
| Oct 6, 2025 | Matthew Winton Chief Commercial and Business | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Oct 8, 2025 |
| Jun 23, 2025 | John J Alam CEO & President | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Spouse | +8,100 | $0.00 | $0 | 8,100 | Jun 25, 2025 |
| Jun 23, 2025 | Joshua S Boger director, owner | AGrant or award Stock Option (Right to Buy)derivative | +8,100 | $0.00 | $0 | 8,100 | Jun 25, 2025 |
| Jun 23, 2025 | Sylvie Gregoire director, owner | AGrant or award Stock Option (Right to Buy)derivative | +8,100 | $0.00 | $0 | 8,100 | Jun 25, 2025 |
| Jun 23, 2025 | Jane H Hollingsworth director | AGrant or award Stock Option (Right to Buy)derivative | +8,100 | $0.00 | $0 | 8,100 | Jun 25, 2025 |
| Jun 23, 2025 | Jeffrey V. Poulton director | AGrant or award Stock Option (Right to Buy)derivative | +8,100 | $0.00 | $0 | 8,100 | Jun 25, 2025 |
| Jun 23, 2025 | Marwan Sabbagh director | AGrant or award Stock Option (Right to Buy)derivative | +8,100 | $0.00 | $0 | 8,100 | Jun 25, 2025 |
| Jun 23, 2025 | Frank Zavrl director | AGrant or award Stock Option (Right to Buy)derivative | +8,100 | $0.00 | $0 | 8,100 | Jun 25, 2025 |
| May 14, 2025 | William Robert Elder CFO, GC & Secretary | POpen-market purchase Common Stock | +4,233 | $8.46 | $36k | 5,500 | May 14, 2025 |
| Feb 4, 2025 | John J Alam CEO & President | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 14, 2025 |
| Feb 4, 2025 | Kelly Blackburn SVP, Clinical Development | AGrant or award Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Feb 14, 2025 |
| Feb 4, 2025 | Robert Joseph Cobuzzi Jr. Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Feb 14, 2025 |
| Feb 4, 2025 | William Robert Elder CFO & GC | AGrant or award Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Feb 14, 2025 |
| Feb 4, 2025 | Sylvie Gregoire director, owner | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Spouse | +60,000 | $0.00 | $0 | 60,000 | Feb 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- John J AlamCEO & President
- Joshua S Bogerdirector, owner
- Kelly BlackburnSVP, Clinical Development
- Robert Joseph Cobuzzi Jr.Chief Operating Officer
- Mark De RoschEVP, RA and GA and PgM
- William Robert ElderGC & Secretary
- Sylvie Gregoiredirector, owner
- Jane H Hollingsworthdirector
- Jeffrey V. Poultoncfo, officer, director
- David Quigleydirector
- Marwan Sabbaghdirector
- Matthew WintonChief Commercial and Business
- Frank Zavrldirector
Questions about CRVO
Answered from the filings on this page, as of the latest one.
Are insiders buying CRVO?
No. In the last 90 days no insider at CervoMed Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CRVO on the open market?
Joshua S Boger (director and 10% owner) bought $3.0M of CRVO on Jun 11, 2026 and filed the Form 4 on Jun 15, 2026. InsiderTell scored 68 (notable).
How many insiders file Form 4 at CervoMed Inc.?
13 people have filed a Form 4 at CervoMed Inc., among them John J Alam (CEO & President), Joshua S Boger (director and 10% owner), Kelly Blackburn (SVP, Clinical Development). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.